Table 2.
Baseline demographics and clinical characteristics of 109 randomized patients
| Epoetin (n=55) | No-Epoetin alfa (n=54) | P-value | |
|---|---|---|---|
|
| |||
| Sex, n (%) | 0.13 | ||
| Male | 33 (58) | 24 (42) | |
| Female | 22 (42) | 30 (58) | |
|
| |||
| Race, n (%) | 0.01 | ||
| Caucasian | 27 (43) | 36 (57) | |
| African American | 1 (25) | 3 (75) | |
| Hispanic | 27 (69) | 12 (31) | |
| Asian | 0 (0) | 3 (100) | |
|
| |||
| Age (years) | 0.63 | ||
| Mean (SD) | 41 (16.7) | 42 (17.3) | |
| Median (range) | 39 (18–76) | 42 (15–84) | |
|
| |||
| Diagnosis, n (%) | 0.15 | ||
| B lymphoblastic leukemia/lymphoma | 38 (47) | 43 (53) | |
| T lymphoblastic leukemia/lymphoma | 8 (73) | 3 (27) | |
| Burkitt leukemia/lymphoma | 9 (60) | 6 (40) | |
| Biphenotypic | 0 (0) | 2 (100) | |
|
| |||
| Bone marrow involvement, n (%) | 0.58 | ||
| Yes | 46 (49) | 48 (51) | |
| No | 9 (60) | 6 (40) | |
|
| |||
| Cytogenetics, n (%) | 0.09 | ||
| Diploid | 25 (58) | 18 (42) | |
| t(9;22) | 6 (29) | 15 (71) | |
| Other | 18 (51) | 17 (49) | |
|
| |||
| Chemotherapy, n (%) | 1.0 | ||
| Hyper-CVAD based regimens | 54 (98) | 52 (96) | |
| Augmented BFM | 1 (2) | 2 (4) | |
|
| |||
| Baseline hemoglobin (g/dl) | .88 | ||
| Mean (SD) | 9 (1.5) | 8.9 (1.5) | |
| Median (range) | 8.8 (6.6–12.5) | 8.7 (6–12.5) | |
|
| |||
| Baseline erythropoietin level | .04 | ||
| Mean (SD) | 473 (570) | 326 (514) | |
| Median (range) | 316 (9.1–3397) | 161 (6.9–3048) | |
|
| |||
| Observation period (weeks) | .72 | ||
| Mean (SD) | 19 (7) | 19 (7.3) | |
| Median (range) | 20 (1–33) | 21 (0–36) | |
|
| |||
| Number of courses of chemotherapy completed | .88 | ||
| Mean (SD) | 5.5 (2.1) | 5.6 (2) | |
| Median (range) | 7 (0–7) | 7 (1–7) | |